期刊文献+

HIV-1逆转录酶抑制剂的3D-QSAR和分子对接研究 被引量:3

Study on 3D-QSAR and molecular docking of HIV-1 reverse transcriptase inhibitors
下载PDF
导出
摘要 采用分子对接和三维定量构效关系研究了二芳基苯胺衍生物与HIV-1非核苷类逆转录酶的相互作用,并运用经典的三维全息原子场作用矢量的方法(3D-HoVAIF)和多元线性回归方法(MLR)研究了药物分子的化学结构与生物活性之间的关系.MLR建模得出的复相关系数(R_(cum))为0.949、留一法交互校验复相关系数(QCV)为0.799,从该结果可以看出,三维定量构效关系对化合物的抗艾滋病活性具有比较好的预测能力.最后,运用分子对接研究了小分子药物和大分子HIV-1逆转录酶的氨基酸活性残基之间的结合模式,对今后设计合成新的抗艾滋病药物具有很好的指导作用. In this study,using molecular docking and three-dimensional quantitative structureactivity relationship as a method to study the interaction between a series of diaryl aniline analogues and HIV-1non nucleoside reverse transcriptase,through the establishment of threedimensional quantitative structure-activity relationship model and multiple linear regression(MLR)model study the relationship between structure and biological activity of the drug moleculesl.The correlation coefficient(R(cum))of MLR is 0.949,the correlation coefficient(QCV)is 0.799,the results show that the three-dimensional quantitative structure-activity relationship has good prediction ability for the anti HIV activity of the compound.The binding model of small molecule drugs and macromolecular HIV-1 reverse transcriptase active amino acid residues was studied by molecular docking.It is a good guide for the design and synthesis of new anti AIDS drugs.
出处 《陕西科技大学学报(自然科学版)》 2016年第2期134-138,共5页 Journal of Shaanxi University of Science & Technology
基金 国家自然科学基金项目(21475081)
关键词 HIV-1逆转录酶 三维定量构效关系 多元线性回归 分子对接 HIV-1 reverse transcriptase three-dimensional quantitative structure-activity relationship multiple linear regression molecular docking
  • 相关文献

参考文献18

  • 1Fatemi M H, Heidari A, Gharaghani S. QSAR prediction of HIV-1 protease inhibitory activities using docking de- rive d molecular descriptors[J]. J Theor Biol, 2015,369: 13-22.
  • 2International C. Global report: UNAIDS report on the global AIDS epidemic 2013[R]. GenevaUNAIDS,2013.
  • 3Corbett J W, Ko S S,Rodgers J D,et al. Inhibition of clini- cally relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors[J]. J Med Chem,2000,43(10) : 193-195.
  • 4Liang Y H,He Q Q,Zeng Z S, et al. Hybrid diarylbenzo- pyrimidine non-nucleoside reverse transeriptase inhibitors as promising new leads for improved anti-HIV-1 chemo- therapy[J]. Bioorg Med Chem, 2010, 18(13): 4 601- 4 605.
  • 5Zeng Z S,He Q Q, Liang Y H,et al. Hybrid diarylbenzo- pyrimidine non-nucleoside reverse transeriptase inhibitors as promising new leads for improved anti-HIV-I chemo- therapy[J]. Bioorg Med Chem, 2010, 18(14); 5 039- 5 047.
  • 6Qin X,Jiang H, Lu X, et al. Diarylaniline derivatives as adistinct class of HIV-2 non-nucleoside reverse tran- scriptase inhibitors[J], J Med Chem,2010,53(13) :4 906- 916.
  • 7Morris G M,Goodsell D S, Halliday R S, et al. Automated docking using a lamarckian genetic algorithm and an em- pirical binding free energy function[J]. Com put. Chem, 1998,19(14):1 639-1 662.
  • 8Bhadoriya K S,Sbarma M C,Jain S V,et al. 2,4-dihydro- 9yrano[2,3-c] pyrazole: Discovery of new lead as through harmaeophore modeling, atom-based 3D-QSAR, virtual creening and docking strategies for improved anti-HIV-1 :hemotherapy[J]. Journal of Taibah University for Sci- mce,2015,44(4):522-530.
  • 9Damme S V, Bultinck P. 3D-QSAR based on conceptual DFT molecular fields: Antituberculotic activity[J]. Jour- nal of Molecular Structure Theochem, 2010,943 ( 1 ) : 83- 89.
  • 10Levitt M. Protein folding by restrained energy minimiza- tion and molecular dynamics[J]. J. Mol. Biol, 1983,170 (3) :723-764.

二级参考文献31

  • 1张娜,蒋勇军,俞庆森,邹建卫.GSK-3抑制剂研究进展[J].化学进展,2007,19(4):614-623. 被引量:11
  • 2Nebert D W, Russell D W. [J]. Lancet, 2002, 360:1 155 - 1 162.
  • 3Ingelman-Sundberg M. [J]. Mutat Res, 2001, 482:1 119.
  • 4Ingelman-Sundberg M. [J]. Naunyn-Schmiedeberg's Arch Pharmacol, 2004, 369:89 - 104.
  • 5Shimada T, Yamazaki H, Mimura M, et al. [J]. Drug Metab Dispos, 1996, 24:515 - 522.
  • 6Hellmold H, Rylander T, Magnusson M, et al. [J]. J Clin Endocrinol Metab, 1998, 83: 886 - 895.
  • 7Nhamburo, Patson T, Shioko Kimura, et al. [J]. Biochemistry, 1990, 29:5 491 - 5 499.
  • 8Lanza D L, Code E, Crespi C L, et al. [J]. Drug Metab Dispos, 1999, 27:798 - 803.
  • 9InsightⅡ, version 98.0, 1998, MSI, San Diego.
  • 10Scott E E, He Y A, Wester M R, et al. [J]. Proc Natl Acad Sci, 2003, 23:13 196 - 13 201.

共引文献5

同被引文献22

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部